Tradestie Institutional Equity Comparison Engine
XBIO vs ACHV โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ACHV Overall Edge
ACHV Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Achieve Life Sciences, Inc. (ACHV) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ACHV
XBIO N/M vs ACHV 35.3x Fwd P/E
Growth & Margin Winner
ACHV
Op Margin -81.0% vs 0.0% ยท YoY +12.0% vs +0.0%
Momentum & Technical Winner
ACHV
1Y -42.0% vs +43.0% ยท 52W Pos 2% vs 69%
Options & Structure Winner
ACHV
UNCLASSIFIED (N/A IV) vs BREAKOUT (23rd %ile IV)
XBIO
NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.49
-10.24% 1D
Market Cap
$3.9M
1M Return
-25.13%
1Y Return
-42.02%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 33.0
Fund 50.0
Flow 50.0
Mom 74.0
ACHV
NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap
$692.8M
1M Return
-8.5%
1Y Return
+43.04%
Forward P/E
35.3x
Unified AI Score
56.6 / 100
HOLD
Tech 66.0
Fund 58.0
Flow 57.0
Mom 58.9
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XBIO -42.02%
ACHV +43.04%
Spread: +78.09 pp (ACHV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
XBIO TTM Op. Margin: -81.0%
ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XBIO vs ACHV. Trailing 12-month operating profitability (XBIO -81.0% vs ACHV 0.0%) and valuation multiples (XBIO N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XBIO | ACHV | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.9M | $692.8M | Larger Scale | ACHV |
| Trailing P/E Ratio Valuation | N/M | 35.3x | Lower Multiple | ACHV |
| Forward P/E Ratio Valuation | N/M | 35.3x | Lower Multiple | ACHV |
| Revenue Growth (YoY) Growth | +12.0% | +0.0% | Higher Growth | XBIO |
| Operating Margin (TTM) Profitability | -81.0% | 0.0% | Higher Margin | ACHV |
| Net Profit Margin Profitability | -75.9% | 0.0% | Higher Margin | ACHV |
| Return on Equity (ROE) Capital Efficiency | -47.0% | -845.0% | Higher ROE | XBIO |
| 52-Week Range Position Momentum | 2% ($1โ$5) | 69% ($3โ$9) | Stronger Trend | ACHV |
| Beta / 30D Volatility Risk Regime | 1.60ฮฒ ยท 97% Vol | 1.73ฮฒ ยท 62% Vol | Lower Realized Risk | ACHV |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 56.6 / 100 (HOLD) | Higher Composite | ACHV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XBIO vs ACHV Buy Guide
XBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ACHV
BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XBIO nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.